BOSTON (TheStreet) -- A desperate, $11 billion Hail Mary acquisition, two botched drug launches, a clueless, tin-eared investor relations strategy, and an expensive and quixotic quest to develop a product no one needs -- these are the transgressions that have earned five executives the dishonor of being nominated for TheStreet's Worst Biotech CEO of 2011 Award.
You, the readers, (the 99%!) will decide which of these five nominees is the worst of the worst and deserves to hold aloft the Nance Trophy.
The five Worst Biotech CEO nominees for 2011 are John Martin of Gilead Sciences (GILD), Mitch Gold, Dendreon (DNDN), Amarin's (AMRN) Joseph Zakrzewski, Al Mann of Mannkind (MNKD) and Gregory Divis Jr. of K-V Pharmaceuticals (KV.A).
The Nance Trophy is named in recognition of David Nance, the former CEO of now bankrupt and defunct Introgen Therapeutics. Few CEOs in biotech did more to hone the fine craft of investor bamboozlement and outright incompetence as Introgen's Nance.Past winners (or should I say losers?) of the Worst Biotech CEO of the Year Award are Elan's (ELN) Kelly Martin in 2008, Genzyme's Henri Termeer in 2009 and Dan Bradbury of Amylin Pharmaceuticals (AMLN) last year. For the 2011 crowning, I'd like readers to cast the deciding votes. Read the following nominating summaries and make your selection in the interactive poll at the end of this story. Feel free also to post comments if you feel I left off a CEO deserving of shame. I'll tally the votes and award the trophy in a week. John Martin, Gilead Sciences: Honest to God truth, I wrote up Martin's nomination for worst biotech CEO on the Sunday afternoon before Gilead announced its audacious and unbelievably expensive $11 billion acquisition of Pharmasset (VRUS). A few days later, I sat down to reassess Martin's status. Did he still deserve the sting of this nomination? Or had he earned a reprieve, perhaps even a nod as a best biotech CEO candidate? I decided that Martin still belongs here. The Pharmasset acquisition may transform Gilead into a hepatitis C drug powerhouse, or it might not. The Hep C treatment landscape is changing so quickly and competition is so intense, predicting which drugs may or not become future fixtures is nearly impossible.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV